Language Network Prehab Via fMRI Neurofeedback
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT07488780
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Glioma
- Glioma Surgery
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- fMRI — DEVICEReal-time functional magnetic resonance imaging (fMRI) neurofeedback (NF)
Study Details
This is an interventional neuroimaging study that will examine whether fMRI neurofeedback can shift language network activity away from regions affected by glioma prior to surgery.
Key Dates
- Start date
- Apr 30, 2026
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 4 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DEVICE_FEASIBILITY
Arms
- Experimental: fMRI neurofeedback (NF) and GliomaAll participants will receive an fMRI NF intervention delivered as a presurgical prehabilitation strategy involving eloquent language cortex. The intervention will be conducted during the standard preoperative window and will not alter or delay clinical care. The study involves repeated within-subject assessments, including baseline and post-intervention neuropsychological testing and task-based fMRI measures.
Primary Outcome Measure
Number of participants enrolled to assess feasibility [ Time Frame: up to 6 months ]
Central Contacts
- Luca Pasquini, MD, PhD203-688-2433
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale School of Medicine | New Haven | Connecticut | 06520 | - |
Find similar trials in New Haven, CT
By condition
By specialty
By research site
Related Studies
- Pembrolizumab, Olaparib, and Temozolomide for People With GliomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Hartford, Connecticut
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)PHASE3 · Recruiting · Nuvation Bio Inc. · Birmingham, Alabama
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)PHASE3 · Recruiting · Jazz Pharmaceuticals · Phoenix, Arizona
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsPHASE1 · Recruiting · Nested Therapeutics, Inc · San Francisco, California